PMID- 21762937 OWN - NLM STAT- MEDLINE DCOM- 20120604 LR - 20240323 IS - 1097-685X (Electronic) IS - 0022-5223 (Print) IS - 0022-5223 (Linking) VI - 143 IP - 5 DP - 2012 May TI - Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn Trial. PG - 1036-42 LID - 10.1016/j.jtcvs.2011.06.014 [doi] AB - BACKGROUND: The CorCap cardiac support device (Acorn Cardiovascular, Inc, St Paul, Minn) is the first device that specifically addresses ventricular remodeling in heart failure by reducing wall stress. We previously reported outcomes from the Acorn randomized trial to a common closing date (22.9 months of follow-up). This report summarizes results of extended followup to 5 years. METHODS: A total of 107 patients were enrolled in the no-mitral valve repair/replacement stratum including 57 in the CorCap treatment group and 50 in the control (optimal medical therapy alone) group. Patients were assessed every year, until completing 5 years of follow-up, for survival, adverse events, major cardiac procedures, New York Heart Association (NYHA) functional status, and echocardiograms, which were read at a core laboratory. RESULTS: Overall survivals were similar between the treatment and control groups, demonstrating no late adverse effect on mortality. The treatment group had significant reductions in left ventricular end-diastolic volume (P = .029) as well as a small increase in sphericity index. More patients in the treatment group improved by at least 1 NYHA functional class (P = .0005). There was no difference in rates of adverse events. In a subgroup of patients with an intermediate left ventricular end-diastolic dimension, there was a significant reduction in the Kaplan-Meier estimate of the freedom from the composite end point of death and major cardiac procedures (P = .04). CONCLUSIONS: These cumulative data demonstrate the sustained reverse remodeling of the left ventricle and the long-term safety and efficacy of the CorCap cardiac support device as an adjunctive therapy for patients with heart failure who remain symptomatic despite optimal medical therapy. CI - Copyright (c) 2012. Published by Mosby, Inc. FAU - Mann, Douglas L AU - Mann DL AD - Division of Cardiology, Washington University School of Medicine, 660 S. Euclid Ave, Campus PO Box 8086, St Louis, MO 63110-1093, USA. dmann@dom.wustl.edu FAU - Kubo, Spencer H AU - Kubo SH FAU - Sabbah, Hani N AU - Sabbah HN FAU - Starling, Randall C AU - Starling RC FAU - Jessup, Mariell AU - Jessup M FAU - Oh, Jae K AU - Oh JK FAU - Acker, Michael A AU - Acker MA LA - eng GR - P01 HL074237/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20110716 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Biomechanical Phenomena MH - Female MH - Heart Failure/mortality/pathology/physiopathology/*therapy MH - *Heart-Assist Devices MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Prospective Studies MH - Prosthesis Design MH - Recovery of Function MH - Risk Assessment MH - Risk Factors MH - Stress, Mechanical MH - Time Factors MH - Treatment Outcome MH - United States MH - *Ventricular Function, Left MH - *Ventricular Remodeling PMC - PMC3790142 MID - NIHMS515870 EDAT- 2011/07/19 06:00 MHDA- 2012/06/05 06:00 PMCR- 2013/10/04 CRDT- 2011/07/19 06:00 PHST- 2010/11/20 00:00 [received] PHST- 2011/05/06 00:00 [revised] PHST- 2011/06/07 00:00 [accepted] PHST- 2011/07/19 06:00 [entrez] PHST- 2011/07/19 06:00 [pubmed] PHST- 2012/06/05 06:00 [medline] PHST- 2013/10/04 00:00 [pmc-release] AID - S0022-5223(11)00633-7 [pii] AID - 10.1016/j.jtcvs.2011.06.014 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2012 May;143(5):1036-42. doi: 10.1016/j.jtcvs.2011.06.014. Epub 2011 Jul 16.